
    
The genomic variant c.1399G>A p.Ala467Thr rs745774658 in the SCN2A gene is a missense variant that results in the substitution of alanine with threonine at the 467th amino acid position. This variant has been identified in individuals presenting with a range of neurological phenotypes, particularly refractory epilepsy with developmental delay. In one study, two probands carrying this variant exhibited similar phenotypes characterized by refractory epilepsy and developmental delay, suggesting a potential pathogenic role for this variant [1]. However, the variant's clinical significance remains uncertain, as it has been submitted to ClinVar with conflicting interpretations, including one benign and three with uncertain significance.The SCN2A gene encodes the alpha-2 subunit of the voltage-gated sodium channel Na_v1.2, which is critical for the initiation and propagation of action potentials in neurons. Na_v1.2 channels are predominantly expressed in the central nervous system and play a key role in neuronal excitability and firing patterns. Mutations in SCN2A can lead to a wide spectrum of neurological disorders, including epilepsy, autism, intellectual disability, and other neurodevelopmental disorders due to their impact on neuronal function.The c.1399G>A p.Ala467Thr variant is located in a region of the SCN2A gene that is important for the function of the sodium channel, and missense mutations in this gene can lead to either gain-of-function or loss-of-function effects, which can disrupt the normal balance of neuronal excitability. The functional implications of the p.Ala467Thr variant specifically have been described in relation to protein instability, and it has been associated with intellectual disability without epilepsy in one study, and with developmental and epileptic encephalopathy in another, highlighting the variable expressivity and incomplete penetrance often observed with SCN2A variants [1].In a genetic study of a monozygotic twin family with generalized epilepsy with febrile seizures plus (GEFS+), the c.1399G>A variant was identified as a new mutation not previously reported in the Human Gene Mutation Database (HGMD). The presence of the mutation correlated with the phenotype in the affected twins, while asymptomatic family members did not harbor this mutation, suggesting a potential pathogenic role [4].In summary, the c.1399G>A p.Ala467Thr rs745774658 variant in the SCN2A gene is a missense change with uncertain clinical significance, implicated in neurological phenotypes such as refractory epilepsy and developmental delay. The SCN2A gene itself is crucial for proper neuronal function, and mutations can have significant impacts on neurodevelopment and neuronal excitability. Further research is needed to fully elucidate the pathogenicity and clinical implications of this specific variant.

SCN2A遺伝子におけるゲノム変異c.1399G>A p.Ala467Thr rs745774658は、ミスセンス変異であり、467番目のアミノ酸位置でアラニンがスレオニンに置換される結果をもたらします。この変異は、特に発達遅延を伴う難治性てんかんを呈する神経学的表現型を持つ個人で確認されています。ある研究では、この変異を持つ2人のプロバンドが難治性てんかんと発達遅延を特徴とする類似の表現型を示し、この変異が病原性を持つ可能性を示唆しています[1]。しかし、この変異の臨床的意義は不確定であり、ClinVarに提出された際には、良性と不確定な意義を含む矛盾した解釈が報告されています。

SCN2A遺伝子は、電位依存性ナトリウムチャネルNa_v1.2のα-2サブユニットをコードしており、ニューロンにおける活動電位の開始と伝播に重要な役割を果たします。Na_v1.2チャネルは主に中枢神経系で発現しており、ニューロンの興奮性や発火パターンにおいて重要な役割を担っています。SCN2A遺伝子の変異は、ニューロン機能への影響により、てんかん、自閉症、知的障害、その他の神経発達障害を含む幅広い神経学的疾患を引き起こす可能性があります。

c.1399G>A p.Ala467Thr変異は、SCN2A遺伝子のナトリウムチャネルの機能に重要な領域に位置しており、この遺伝子のミスセンス変異は、ニューロンの興奮性の正常なバランスを乱す可能性のある機能獲得型または機能喪失型の影響を引き起こすことがあります。特にp.Ala467Thr変異の機能的影響は、タンパク質の不安定性に関連して記述されており、ある研究ではてんかんを伴わない知的障害と関連付けられ、別の研究では発達性およびてんかん性脳症と関連付けられています。このことは、SCN2A変異にしばしば見られる変異の表現型の多様性と不完全浸透性を強調しています[1]。

全身性てんかんと熱性けいれんプラス（GEFS+）を持つ一卵性双生児家族の遺伝学的研究では、c.1399G>A変異がヒト遺伝子変異データベース（HGMD）で以前に報告されていない新しい変異として確認されました。この変異は影響を受けた双生児の表現型と相関しており、無症状の家族メンバーにはこの変異が存在しなかったため、病原性の可能性が示唆されています[4]。

まとめると、SCN2A遺伝子のc.1399G>A p.Ala467Thr rs745774658変異は臨床的意義が不確定なミスセンス変異であり、難治性てんかんや発達遅延などの神経学的表現型に関連しています。SCN2A遺伝子自体は適切なニューロン機能にとって重要であり、その変異は神経発達やニューロンの興奮性に重大な影響を与える可能性があります。この特定の変異の病原性と臨床的影響を完全に解明するためには、さらなる研究が必要です。
    
## References
- [1] Viswanathan LG et al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Helbig I et al. (2020). "Whole-exome and HLA sequencing in Febrile infection-related epilepsy syndrome." Annals of clinical and translational neurology, 7(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32666661/)
- [3] Menezes LFS et al. (2020). "Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review." Frontiers in pharmacology, 11() [PubMed](https://pubmed.ncbi.nlm.nih.gov/33013363/)
- [4] Liu XW et al. (2018). "The finding of a new heterozygous mutation site of the SCN2A gene in a monozygotic twin family carrying and exhibiting genetic epilepsy with febrile seizures plus (GEFS+) using targeted next-generation sequencing." Clinical neurology and neurosurgery, 169() [PubMed](https://pubmed.ncbi.nlm.nih.gov/29635106/)
- [5] Kuczynski EA et al. (2022). "A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability." EMBO molecular medicine, 14(6) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/35510955/)
- [6] Giannakis M et al. (2016). "Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma." Cell reports, 15(4) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/27149842/)
- [7] Sveen A et al. (2017). "Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1." Genome medicine, 9(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/28539123/)
- [8] Xie M et al. (2014). "Age-related mutations associated with clonal hematopoietic expansion and malignancies." Nature medicine, 20(12) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25326804/)
- [9] Lu C et al. (2015). "Patterns and functional implications of rare germline variants across 12 cancer types." Nature communications, 6() [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/26689913/)
- [10] Triki M et al. (2020). "mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis." Cell reports, 31(12) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/32579932/)

    
## ClinVar Submissions
- **[RCV001214677](https://www.ncbi.nlm.nih.gov/clinvar/RCV001214677/)**: Seizures, benign familial infantile, 3 (and 1 more)
- **[RCV001529557](https://www.ncbi.nlm.nih.gov/clinvar/RCV001529557/)**: not provided
- **[RCV001542304](https://www.ncbi.nlm.nih.gov/clinvar/RCV001542304/)**: Developmental and epileptic encephalopathy, 11
- **[RCV001263092](https://www.ncbi.nlm.nih.gov/clinvar/RCV001263092/)**: Seizure
- **[RCV000522032](https://www.ncbi.nlm.nih.gov/clinvar/RCV000522032/)**: not provided

    